Cidara Therapeutics Inc.
Cidara Therapeutics Signs Agreement with BARDA for CD388 Development
Summary
On September 30, 2025, Cidara Therapeutics, Inc. entered into a significant agreement with the Biomedical Advanced Research and Development Authority (BARDA) to support the expanded manufacturing and clinical development of CD388, a non-vaccine influenza preventative therapeutic. The BARDA Agreement includes potential investments by BARDA of up to $339.2 million over a period that may extend through July 3, 2030, contingent on the exercise of certain options. This collaboration aims to support onshoring of CD388 manufacturing in the U.S. and conduct clinical trials to assess CD388's effectiveness against pandemic influenza strains.
Profitelligence Alerts
Get alerts for CDTX
Be first to know when Cidara Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Cidara Therapeutics Inc.
Cidara Therapeutics Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives and immunotherapies. Its primary function involves addressing unmet medical needs in the treatment of serious infectious diseases and immune-based conditions. Emphasizing innovation, Cidara Therapeutics is known for its pioneering Cloudbreak platform, which integrates potent drug conjugates designed to address life-threatening bacterial, viral, and fungal infections. The asset prominently impacts the biotechnology and pharmaceutical sectors, endeavoring to transform standard infection treatments with its advanced therapeutic solutions. Cidara's pipeline includes the development of new antifungal agents like rezafungin, aimed at treating invasive fungal infections that significantly affect immunocompromised patients. With its strategic focus, Cidara Therapeutics plays a critical role in the emerging markets of antimicrobial resistance and immunotherapy. Positioned within the healthcare industry, Cidara's contributions hold significant potential to alter existing therapies and specialize in meeting complex medical challenges, reinforcing the broader landscape of pharmaceutical advancements and patient care strategies.
Official SEC Documents
Advertisement